Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $22.00 price objective on the stock.

YMAB has been the subject of several other reports. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. BMO Capital Markets lowered their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Morgan Stanley lowered their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.38.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $10.72 on Friday. The firm’s 50 day moving average price is $13.93 and its 200-day moving average price is $13.01. The company has a market cap of $480.14 million, a PE ratio of -19.85 and a beta of 0.68. Y-mAbs Therapeutics has a 52-week low of $5.17 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the prior year, the company posted ($0.18) EPS. On average, analysts forecast that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 14.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,000 shares of company stock worth $1,338,100. Company insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Empire Financial Management Company LLC purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter worth $210,000. Geode Capital Management LLC increased its stake in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Barclays PLC increased its stake in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after purchasing an additional 56,244 shares in the last quarter. State Street Corp increased its stake in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP increased its stake in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.